Gastric Cancer: Detection and Prevention

Authors

DOI:

https://doi.org/10.22516/25007440.1399

Keywords:

Gastric cancer, screening, early detection, disease prevention, Helicobacter pylori, risk factors

Abstract

Models for both primary and secondary prevention of gastric cancer have been proposed. However, at least in Western countries, these strategies have not been widely implemented at a scale sufficient to achieve the anticipated public health impact. This article offers a reflective overview of the disease’s natural history, primary and secondary prevention concepts, risk-stratification strategies, and screening approaches, with particular emphasis on endoscopy and eradication of Helicobacter pylori. The article also discusses considerations for regions with intermediate incidence rates. Several of these strategies have been successfully adopted in other parts of the world as global prevention measures aimed at reducing the current and future burden of gastric cancer.

Downloads

Download data is not yet available.

Author Biographies

Ricardo Oliveros Wilches, Instituto Nacional de Cancerología

Gastrointestinal Surgeon. Advisor, National Cancer Institute. Bogotá, Colombia.

Helena Facundo Navia, Instituto Nacional de Cancerología

Specialist in Gastrointestinal Surgery and Digestive Endoscopy. Specialist Physician, National Cancer Institute. Bogotá, Colombia.

Raúl Eduardo Pinilla Morales, Instituto Nacional de Cancerología

Physician, General Surgeon, Gastroenterologist, and Digestive Endoscopist, National Cancer Institute. Specialist Physician, Clínica Méderi and Clínica del Country. Assistant Professor of Surgery, Universidad Nacional de Colombia. Bogotá, Colombia.

Ana Deise Bonilla Castañeda, Instituto Nacional de Cancerología

Physician and Surgeon, General Surgeon, Gastrointestinal Surgeon, National Cancer Institute. Bogotá, Colombia.

Gustavo Adolfo Aguirre Bermudez, Instituto Nacional de Cancerología

Physician and General Surgeon, Gastrointestinal Surgeon, and Digestive Endoscopist. Specialist in Education for Clinicians, Fellow of the American College of Surgeons. Gastrointestinal Surgeon, National Cancer Institute. Bogotá, Colombia.

References

Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M, Uggeri F. Early Gastric Cancer: Update on Prevention, Diagnosis and Treatment. Int J Environ Res Public Health. 2023;20(3):2149. https://doi.org/10.3390/ijerph20032149

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834

Januszewicz W, Turkot MH, Malfertheiner P, Regula J. A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When? Cancers (Basel). 2023;15(3):664. https://doi.org/10.3390/cancers15030664

Laudano O RAMJP. Prevención del cáncer gástrico: contexto y experiencia latinoamericana. Acta Gastroenterol Latinoam. 2024;54(4):299-399. https://doi.org/10.52787/agl.v54i4.456

Hamashima C. Forthcoming Step in Gastric Cancer Prevention: How Can Risk Stratification Be Combined with Endoscopic Screening for Gastric Cancer? Gut Liver. 2022;16(6):811-824. https://doi.org/10.5009/gnl210313

Bedoya Á, Sansón F, Yépez Fuertes Y, Santacruz C, Cifuentes Y, Calvache D, et al. Prevalencia y severidad de las lesiones precursoras de malignidad en una área de alto riesgo de cáncer gástrico. Pasto 2012;27(4): 275-281.

Rugge M SESMBLMP. Gastritis: the clinic pathological spectrum. Dig Liver Dis. 2021;53(10):1237-46. https://doi.org/10.1016/j.dld.2021.03.007

Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093-2112. https://doi.org/10.1136/gutjnl-2020-322368

Marqués-Lespier JM, González-Pons M, Cruz-Correa M. Current Perspectives on Gastric Cancer. Gastroenterol Clin North Am. 2016;45(3):413-28. https://doi.org/10.1016/j.gtc.2016.04.002

Venerito M, Vasapolli R, Malfertheiner P. Helicobacter pylori and Gastric Cancer: Timing and Impact of Preventive Measures. Adv Exp Med Biol. 2016;908:409-18. https://doi.org/10.1007/978-3-319-41388-4_20

Chiang TH, Cheng HC, Chuang SL, Chen YR, Hsu YH, Hsu TH, et al. Mass screening and eradication of Helicobacter pylori as the policy recommendations for gastric cancer prevention. J Formos Med Assoc. 2022;121(12):2378-2392. https://doi.org/10.1016/j.jfma.2022.08.012

Hu Y, Zhu Y, Lu NH. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China. Front Cell Infect Microbiol. 2022;12:1049279. https://doi.org/10.3389/fcimb.2022.1049279

Safarty D. Preventing cancer: the only way forward. Comment. Lancet. 2022;20(400):540-1. https://doi.org/10.1016/S0140-6736(22)01430-1

GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10352):563-591. https://doi.org/10.1016/S0140-6736(22)01438-6

Kotelevets SM. Global strategy for prevention of gastric cancer. World J Clin Cases. 2024;12(30):6353-7. https://doi.org/10.12998/wjcc.v12.i30.6353

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. https://doi.org/10.1136/gutjnl-2015-309252

Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5):e12415. https://doi.org/10.1111/hel.12415

Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. https://doi.org/10.1136/bmj.g3174

Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166-75. https://doi.org/10.1007/s10120-015-0462-7

Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, et al. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up. Gastroenterology. 2022;163(1):154-162.e3. https://doi.org/10.1053/j.gastro.2022.03.039

Chiang TH, Chang WJ, Chen SLS, Yen AMF, Fann JCY, Chiu SYH, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands. Gut. 2021;70(2):243-50. https://doi.org/10.1136/gutjnl-2020-322200

Cai Q, Zhu C, Yuan Y, Feng Q, Feng Y, Hao Y, et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: A nationwide multicentre study. Gut. 2019;68(9):1576-87. https://doi.org/10.1136/gutjnl-2018-317556

Oliveros Wilches R, Facundo Navia H, Bonilla Castañeda AD, Pinilla Morales RE. Factores de riesgo para cáncer gástrico: ¿cuál es su papel?. Rev Colomb Gastroenterol. 2021;36(3):366-7. https://doi.org/10.22516/25007440.656

24. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250-60. https://doi.org/10.1111/apt.12814

Lee YC, Chiang TH, Chiu HM, Wu MS, Yeh YP, Hsiu-Hsi Chen T; et al. Community-Based Gastric Cancer Screening Coupled With a National Colorectal Cancer Screening Program: Baseline Results. Gastroenterology. 2021;160(6):2159-2161.e4. https://doi.org/10.1053/j.gastro.2021.01.008

Arias Sosa LC, Cuspoca-Orduz AF, Siabato Barrios JA, Eslava-Roa JS. Incidencia y mortalidad del cáncer gástrico en el departamento de Boyacá-Colombia. Acta Gastroenterol Latinoam. 2018;48(3):181-9.

Bedoya-Urresta Á, Yépez Y, Calvache D, Cifuentes Y, Lucero N, González P, et al. Proyecto Urkunina 5000-Investigación de la prevalencia de lesiones precursoras y del efecto de la erradicación de Helicobacter pylori como prevención primaria del cáncer gástrico en el departamento de Nariño. Revista Colombiana de Cirugía. 2018;33(4):345-52. https://doi.org/10.30944/20117582.81

Leja M. Where are we with gastric cancer screening in Europe in 2024? Gut. 2024;73(12):2074-82. https://doi.org/10.1136/gutjnl-2024-332705

Lin KD, Chiu GF, Waljee AK, Owyang SY, El-Zaatari M, Bishu S, et al. Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019;17(10):1991-1999. https://doi.org/10.1016/j.cgh.2018.12.014

Tabla 1. Programas de tamizaje para cáncer gástrico en países con alto riesgo

Published

2025-12-23

How to Cite

Oliveros Wilches, R., Facundo Navia, H., Pinilla Morales, R. E., Bonilla Castañeda, A. D., & Aguirre Bermudez, G. A. (2025). Gastric Cancer: Detection and Prevention. Revista Colombiana De Gastroenterología, 40(4), 463–471. https://doi.org/10.22516/25007440.1399

Issue

Section

Review articles

Altmetric

Escanea para compartir
QR Code
Article metrics
Abstract views2622
Galley views1771
PDF Views1220
HTML views0
Other views551

Some similar items: